Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03442556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03442556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
August 24, 2018
Completion date
June 4, 2025
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atm gene mutation, brca1 gene mutation, brca2 gene mutation, castration levels of testosterone, castration-resistant prostate carcinoma, homologous recombination deficiency, prostate carcinoma metastatic in the bone, psa level greater than or equal to two, psa progression, stage iv prostate adenocarcinoma ajcc v7